Transgene

CompanyFrance

Transgene develops one asset, in phase 1 (MVA-HCV in chronic hepatitis c). Mostly vaccine acting on inflammation; based in France.

Assets
1
Furthest
Phase 1
Trials
2
Signals
0

Pipeline

1

  • MVA-HCV

    Modified vaccinia Ankara viral vector expressing hepatitis C virus antigens to elicit immune response.

    Phase 1VaccineInflammationchronic hepatitis c

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials2
  • Integrity notices2
  • Similar companies6

Updated 7 Oct 2026 · 5 sources

Intelligence